Status:
RECRUITING
A Study on Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)
Lead Sponsor:
Fudan University
Conditions:
Metastatic Colorectal Cancer
BRAF V600 Mutation
Eligibility:
All Genders
18+ years
Brief Summary
Previous studies have shown that BRAFV600E mutant mCRC patients have a shorter survival time than BRAF wild type mCRC patients. For Chinese patients, however, it remains unclear about the BRAF gene mu...
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of histologically or cytologically confirmed CRC that is metastatic and unresectable
- Presence of BRAFV600E mutation in tumor tissue, as confirmed by a local assay
Exclusion Criteria:
- patients with previous chronic inflammatory bowel disease, chronic diarrhea or recurrent bowel obstruction patients with symptomatic brain metastases active clinical severe infection
Key Trial Info
Start Date :
March 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06749015
Start Date
March 1 2021
End Date
October 1 2026
Last Update
December 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200032